Mutation of the p53 gene is a critical event in the elaboration of many tumors of diverse origin. Alterations in components of the p53 pathway, such as amplification of the mdm2 gene which encodes a p53 inhibitor, have also been found in human tumors. The p53 protein is activated in response to DNA damage and serves a checkpoint function to eliminate or repair cells with damaged DNA. Several upstream signals posttranslationally modify p53 in response to stress. Modifications included phosphorylation at the amino terminus to dislodge the negative inhibitor, MDM2, and the carboxyl terminus to activate the intrinsic DNA binding activity of p53. Due to the large number of phosphorylated amino acids, a combination of modifications may activate p53 and may specify which pathway, growth arrest or apoptosis, to initiate.
The first aim i s to determine how posttranslational modifications and/or protein-protein interactions regulate the activity of p53 and determining its ability to activate specific targets. Another novel mechanism of activating p53 in response to UV damage appears to be the generation of small MDM2 proteins that can bind full-length MDM2 effectively removing it from the cell. Thus, the second aim will be to examine the ability of altered MDM2 products to activate p53 in response to different DNA-damaging agents and independently of other mechanisms that activate p53. Since loss of mdm2 results in p53-mediated embryo lethality, they have also generated a conditional allele of mdm2 to examine the requirement for mdm2 in dividing and non-dividing cells. In this aim they plan to cross mice expressing a conditional mdm2 allele to mice expressing Cre in cycling thymocytes or in differentiated muscle cells. The experiments proposed in this application will examine critical regulators of p53 such as post translational modifications and interactions with MDM2 in determining p53 activity.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA047296-14
Application #
6263160
Study Section
Pathology B Study Section (PTHB)
Program Officer
Mietz, Judy
Project Start
1988-07-01
Project End
2006-02-28
Budget Start
2001-05-31
Budget End
2002-02-28
Support Year
14
Fiscal Year
2001
Total Cost
$249,000
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Genetics
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Ortiz, G J; Li, Y; Post, S M et al. (2018) Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes. Oncogene 37:332-340
Wasylishen, Amanda R; Estrella, Jeannelyn S; Pant, Vinod et al. (2018) Daxx Functions Are p53-Independent In Vivo. Mol Cancer Res 16:1523-1529
Ortiz, Guadalupe J; Lozano, Guillermina (2018) SNPing away at mutant p53 activities. Genes Dev 32:195-196
Pant, Vinod; Larsson, Connie A; Aryal, Neeraj et al. (2017) Tumorigenesis promotes Mdm4-S overexpression. Oncotarget 8:25837-25847
Aryal, Neeraj K; Wasylishen, Amanda R; Pant, Vinod et al. (2017) Loss of digestive organ expansion factor (Diexf) reveals an essential role during murine embryonic development that is independent of p53. Oncotarget 8:103996-104006
Xiong, Shunbin; Pant, Vinod; Zhang, Yun et al. (2017) The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis. J Pathol 241:501-510
Pant, V; Xiong, S; Chau, G et al. (2016) Distinct downstream targets manifest p53-dependent pathologies in mice. Oncogene 35:5713-5721
Mancini, F; Pieroni, L; Monteleone, V et al. (2016) MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response. Oncogene 35:228-40
Riley, M F; You, M J; Multani, A S et al. (2016) Mdm2 overexpression and p73 loss exacerbate genomic instability and dampen apoptosis, resulting in B-cell lymphoma. Oncogene 35:358-65
Tashakori, Mehrnoosh; Zhang, Yun; Xiong, Shunbin et al. (2016) p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis. Mol Cancer Res 14:56-65

Showing the most recent 10 out of 29 publications